Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lotus Tissue Repair Inc.

Latest From Lotus Tissue Repair Inc.

FDA Breakthrough Designation Generates Big Meetings, Big Results, Scioderm Says

Biotech start-up met with 22 agency officials to discuss development of its compound for treatment of epidermolysis bullosa, a rare, genetic connective tissue disorder.

Clinical Trials Regulation

FDA Breakthrough Designation Generates Big Meetings, Big Results, Scioderm Says

Biotech start-up met with 22 agency officials to discuss development of its compound for treatment of epidermolysis bullosa, a rare, genetic connective tissue disorder.

BioPharmaceutical United States

Spurring Innovation While Economizing On R&D Spending Remains Industry-Wide Challenge

Cash is still “cheap” but biopharma M&A continues to move slowly – mid-cap industry execs tell “The Pink Sheet” partly because there is so much competition to acquire the best assets. Meanwhile, most companies are economizing on R&D even as they strive to develop the products that will carry them into the next decade.

BioPharmaceutical United States

2013 Deals Review Finds Spec Pharma, Bolt-Ons Dominated M&A

According to the Strategic Transactions database, 2013 saw 92 deals involving biopharma M&A completed or close to completion; the most active participants were specialty pharma companies, with only a handful of big pharmas committing to buying up assets.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register